The Patient's Voice

Prostate cancer on the cusp of change

August 01, 2010

The author reflects on enrolling in a clinical trial comparing active surveillance with immediate intervention in men with favorable-risk prostate cancer.
 

Dancing Cancer

Linda McDonald June 15, 2010

The author describes the children's book she wrote to make it easier to talk to children about cancer.
 

My cancer journey

JohnMcClelland May 01, 2010

The author describes his experience with colon cancer and the important role oncology nurses have played in his battle with his disease.
 

Free CE from myCME.com

Discussions on Emerging Concepts and Controversies in the Treatment of Patients with Advanced Non-Small Cell Lung Cancer

2.00 / AMA PRA Category 1 Credit(s)TM
This program reviews developments in maintenance therapy and evaluates the relevance of tumor histology and biomarker analysis for the management of NSCLC patients.
 

Cancer care is expensive.
CancerCare can help.


Connect Booklets
Visit Reflections for first-hand stories on the power of the patient to impact caregivers in oncology nursing.
FEBRUARY 3 - 4
• 2012 Highlights of ASH in North America
New York, New York
• 2012 Highlights of ASH in North America
San Francisco, California
MARCH 3 - 4
• 2012 Highlights of ASH in Asia
Singapore, Singapore
MAY 3 - 6
• 37th Annual ONS Congress
New Orleans, Louisiana
 Subscribe to the RSS for this page  [view all our RSS feeds here]

Web Exclusives

Psychosocial approach useful in managing cancer pain

February 03, 2012

Psychosocial interventions, including skills instruction and education, can help reduce pain in persons with cancer, confirm the results of a recent meta-analysis.
 

Experimental agent slows progression of colorectal cancer

February 02, 2012

The investigational drug regorafenib conferred a statistically significant survival benefit in patients with metastatic colorectal cancer in whom no standard therapy was effective.
 

In HER2 breast cancer, lapatinib works better with trastuzumab than without

February 01, 2012

Lapatinib is not as effective as trastuzumab against (HER2)-positive breast cancer, but combining the two nearly doubles the effectiveness seen with either one alone.
 

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization.

Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions